Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain - PubMed (original) (raw)
Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain
P U Daniels-Holgate et al. J Neurosci Res. 1996.
Abstract
Botulinum neurotoxin type A, a di-chain protein produced by Clostridium botulinum and responsible for botulism, blocks acetylcholine release from peripheral nerves by binding to the terminals, undergoing internalization and proteolyzing a protein essential for exocytosis. As butolinum neurotoxin is being used clinically for the treatment of dystonias and certain spasticities, deciphering the details of its specific targeting to cholinergic nerve endings has assumed great importance. Thus, interaction of butolinum neurotoxin type A with murine motor nerve terminals-a prime target in vivo-was investigated. Autoradiographic analysis revealed saturable, high-affinity interaction of radioiodinated toxin (0.4 nM) with two ecto-acceptor types, distinguished by an excess of the toxin's heavy chain which prevented only a fraction of this binding. Botulinum neurotoxin was also biotinylated through its free sulfhydryl groups, known not to be essential for neurotoxicity. Similar binding of this active derivative was, likewise, partially blocked by heavy chain, confirming the above results. This binding that is resistant to heavy chain equates to botulinum neurotoxin interacting with productive ecto-acceptors, leading to delivery to its cytosolic site of action, because heavy chain proved unable to antagonize toxin-induced neuromuscular paralysis. In contrast, it is deduced that botulinum neurotoxin bound to heavy chain-susceptible sites has a different fate, presumably due to trafficking via another route, and thus would be inefficient in causing neuroparalysis.
Similar articles
- Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons.
Poulain B, Wadsworth JD, Shone CC, Mochida S, Lande S, Melling J, Dolly JO, Tauc L. Poulain B, et al. J Biol Chem. 1989 Dec 25;264(36):21928-33. J Biol Chem. 1989. PMID: 2574722 - Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization.
Dolly JO, Black J, Williams RS, Melling J. Dolly JO, et al. Nature. 1984 Feb 2-8;307(5950):457-60. doi: 10.1038/307457a0. Nature. 1984. PMID: 6694738 - The structure and mode of action of different botulinum toxins.
Dolly JO, Aoki KR. Dolly JO, et al. Eur J Neurol. 2006 Dec;13 Suppl 4:1-9. doi: 10.1111/j.1468-1331.2006.01648.x. Eur J Neurol. 2006. PMID: 17112344 Review. - Botulinum neurotoxin: the neuromuscular junction revisited.
Coffield JA. Coffield JA. Crit Rev Neurobiol. 2003;15(3-4):175-96. doi: 10.1615/critrevneurobiol.v15.i34.10. Crit Rev Neurobiol. 2003. PMID: 15248810 Review.
Cited by
- Endomicroscopy and electromyography of neuromuscular junctions in situ.
Brown R, Dissanayake KN, Skehel PA, Ribchester RR. Brown R, et al. Ann Clin Transl Neurol. 2014 Nov;1(11):867-83. doi: 10.1002/acn3.124. Epub 2014 Oct 10. Ann Clin Transl Neurol. 2014. PMID: 25540801 Free PMC article. - An efficient drug delivery vehicle for botulism countermeasure.
Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. Zhang P, et al. BMC Pharmacol. 2009 Oct 27;9:12. doi: 10.1186/1471-2210-9-12. BMC Pharmacol. 2009. PMID: 19860869 Free PMC article. - Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.
Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, Rossetto O, Caleo M, Schiavo G. Restani L, et al. PLoS Pathog. 2012 Dec;8(12):e1003087. doi: 10.1371/journal.ppat.1003087. Epub 2012 Dec 27. PLoS Pathog. 2012. PMID: 23300443 Free PMC article. - Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component.
Park JB, Simpson LL. Park JB, et al. Infect Immun. 2003 Mar;71(3):1147-54. doi: 10.1128/IAI.71.3.1147-1154.2003. Infect Immun. 2003. PMID: 12595426 Free PMC article. - Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Amersdorfer P, et al. Infect Immun. 1997 Sep;65(9):3743-52. doi: 10.1128/iai.65.9.3743-3752.1997. Infect Immun. 1997. PMID: 9284147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials